<p>Rezolute, Inc.（纳斯达克代码：RZLT - 获取免费报告）首席执行官 Nevan Elam 于 12 月 15 日星期一购买了 32,000 股公司股票。该股票的平均购买成本为每股 1.59 美元，总交易额为 50,880.00 美元。交易完成后，首席执行官在公司拥有 641,119 股，价值 1,019,379.21 美元。这代表其持股增加了 5.25%。此次收购已在提交给证券交易委员会的文件中披露，相关文件可在 SEC 网站上查阅。</p>
<h2>Rezolute 股票表现</h2>
<ul>
<li>Rezolute 股票：FDA 快速通道助力 2025 年突破</li>
</ul>
<p>在周一的午盘交易中，RZLT 下跌 0.17 美元，达到 1.63 美元。公司交易了 13,380,965 股，而其平均交易量为 9,712,468 股。该公司的市值为 1.5115 亿美元，市盈率为-1.75，贝塔值为 0.21。Rezolute, Inc.的年内最低价为 1.07 美元，最高价为 11.46 美元。公司的 50 日移动平均价格为 9.00 美元，200 日移动平均价格为 7.17 美元。</p>
<p>Rezolute（纳斯达克代码：RZLT - 获取免费报告）最近一次公布财报是在 11 月 6 日星期四。公司报告本季度每股收益（EPS）为-0.18 美元，超出市场共识预期的-0.27 美元，超出幅度为 0.09 美元。整体来看，卖方分析师预计 Rezolute, Inc.在当前财政年度的每股收益为-0.93 美元。</p>
<h2>分析师评级变动</h2>
<p>RZLT 已成为多份分析师报告的主题。Cantor Fitzgerald 在周四的报告中将 Rezolute 的股票评级从 “增持” 下调至 “中性”。Wedbush 在周四的研究报告中将 Rezolute 的股票评级从 “跑赢大盘” 下调至 “中性”。BTIG Research 在周四的报告中重申了对 Rezolute 的 “买入” 评级，并给出了 5.00 美元的目标价。Citizens Jmp 在周四的报告中将 Rezolute 的评级从 “强烈买入” 下调至 “持有”。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Rezolute 的 “卖出（d-）” 评级。六位研究分析师对该股票给予了买入评级，五位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价为 9.78 美元。</p>
<p><strong>阅读我们关于 Rezolute 的最新股票报告</strong></p>
<h2>机构投资者对 Rezolute 的看法</h2>
<p>几家对冲基金和其他机构投资者最近修改了对该股票的持有情况。BNP Paribas Financial Markets 在第二季度购买了 Rezolute 的新头寸，价值约为 25,000 美元。Ameritas Investment Partners Inc.在第二季度购买了 Rezolute 的新头寸，价值约为 30,000 美元。Legal &amp; General Group Plc 在第二季度购买了 Rezolute 的新股份，价值约为 32,000 美元。Raymond James Financial Inc.在第二季度购买了 Rezolute 的新头寸，价值为 46,000 美元。最后，Paloma Partners Management Co 在第一季度购买了 Rezolute 的新头寸，价值为 48,000 美元。目前，82.97% 的股票由机构投资者持有。</p>
<h2>关于 Rezolute</h2>
<p>（获取免费报告）</p>
<p>Rezolute, Inc.是一家临床阶段的生物制药公司，专注于开发治疗与慢性葡萄糖失衡相关的代谢疾病的疗法。该公司的主要产品候选药物是 RZ358，一种人源单克隆抗体，目前正在进行针对先天性高胰岛素血症的 2b 期临床试验，这是一种极为罕见的儿童遗传疾病。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Rezolute 更好</li>
<li>商业服务股票投资</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>戴尔和惠普正在涨价——投资者应注意</li>
<li>欧元区 STOXX 50 指数是什么？</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlpMVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlpMVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Rezolute 吗？</h2>
<p>在考虑 Rezolute 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Rezolute 并不在名单上。</p>
<p>虽然 Rezolute 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

RZLT

<p>Rezolute, Inc. 首席执行官 Nevan Elam 以每股 1.59 美元的价格购买了 32,000 股公司股票，总计 50,880 美元。这使他的持股增加了 5.25%，现在拥有 641,119 股，价值 1,019,379.21 美元。此次购买在 SEC 文件中披露。还讨论了 Rezolute 的股票表现和分析师评级，普遍评级为 “持有”，目标价格为 9.78 美元。机构投资者已调整其持股，其中 82.97% 的股票由他们持有</p>

<p>Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) CEO Nevan Elam purchased 32,000 shares of the company's stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average cost of $1.59 per share, for a total transaction of $50,880.00. Following the transaction, the chief executive officer owned 641,119 shares in the company, valued at $1,019,379.21. This represents a 5.25% increase in their position. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website.</p>
<div class="lb-trans"><p>Rezolute, Inc.（纳斯达克代码：RZLT - 获取免费报告）首席执行官 Nevan Elam 于 12 月 15 日星期一购买了 32,000 股公司股票。该股票的平均购买成本为每股 1.59 美元，总交易额为 50,880.00 美元。交易完成后，首席执行官在公司拥有 641,119 股，价值 1,019,379.21 美元。这代表其持股增加了 5.25%。此次收购已在提交给证券交易委员会的文件中披露，相关文件可在 SEC 网站上查阅。</p>
</div><h2>Rezolute Stock Performance</h2>
<div class="lb-trans"><h2>Rezolute 股票表现</h2>
</div><ul>
<li>Rezolute Stock: FDA Fast Track Fuels 2025 Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>Rezolute 股票：FDA 快速通道助力 2025 年突破</li>
</ul>
</div><p>RZLT traded down $0.17 during midday trading on Monday, reaching $1.63. 13,380,965 shares of the company were exchanged, compared to its average volume of 9,712,468. The company has a market cap of $151.15 million, a price-to-earnings ratio of -1.75 and a beta of 0.21. Rezolute, Inc. has a one year low of $1.07 and a one year high of $11.46. The company's fifty day moving average price is $9.00 and its 200 day moving average price is $7.17.</p>
<div class="lb-trans"><p>在周一的午盘交易中，RZLT 下跌 0.17 美元，达到 1.63 美元。公司交易了 13,380,965 股，而其平均交易量为 9,712,468 股。该公司的市值为 1.5115 亿美元，市盈率为-1.75，贝塔值为 0.21。Rezolute, Inc.的年内最低价为 1.07 美元，最高价为 11.46 美元。公司的 50 日移动平均价格为 9.00 美元，200 日移动平均价格为 7.17 美元。</p>
</div><p>Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.09. As a group, sell-side analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Rezolute（纳斯达克代码：RZLT - 获取免费报告）最近一次公布财报是在 11 月 6 日星期四。公司报告本季度每股收益（EPS）为-0.18 美元，超出市场共识预期的-0.27 美元，超出幅度为 0.09 美元。整体来看，卖方分析师预计 Rezolute, Inc.在当前财政年度的每股收益为-0.93 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>RZLT has been the subject of several analyst reports. Cantor Fitzgerald downgraded shares of Rezolute from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating in a report on Thursday. Wedbush cut shares of Rezolute from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating in a research report on Thursday. BTIG Research reaffirmed a &#34;buy&#34; rating and issued a $5.00 target price on shares of Rezolute in a report on Thursday. Citizens Jmp lowered Rezolute from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Rezolute in a research note on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Hold&#34; and a consensus target price of $9.78.</p>
<div class="lb-trans"><p>RZLT 已成为多份分析师报告的主题。Cantor Fitzgerald 在周四的报告中将 Rezolute 的股票评级从 “增持” 下调至 “中性”。Wedbush 在周四的研究报告中将 Rezolute 的股票评级从 “跑赢大盘” 下调至 “中性”。BTIG Research 在周四的报告中重申了对 Rezolute 的 “买入” 评级，并给出了 5.00 美元的目标价。Citizens Jmp 在周四的报告中将 Rezolute 的评级从 “强烈买入” 下调至 “持有”。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Rezolute 的 “卖出（d-）” 评级。六位研究分析师对该股票给予了买入评级，五位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “持有”，共识目标价为 9.78 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Rezolute</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Rezolute 的最新股票报告</strong></p>
</div><h2>Institutional Investors Weigh In On Rezolute</h2>
<div class="lb-trans"><h2>机构投资者对 Rezolute 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in shares of Rezolute in the second quarter valued at approximately $25,000. Ameritas Investment Partners Inc. bought a new position in shares of Rezolute in the second quarter worth approximately $30,000. Legal &amp; General Group Plc bought a new stake in Rezolute during the second quarter valued at approximately $32,000. Raymond James Financial Inc. bought a new position in shares of Rezolute in the 2nd quarter worth $46,000. Finally, Paloma Partners Management Co bought a new position in shares of Rezolute in the 1st quarter worth $48,000. 82.97% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近修改了对该股票的持有情况。BNP Paribas Financial Markets 在第二季度购买了 Rezolute 的新头寸，价值约为 25,000 美元。Ameritas Investment Partners Inc.在第二季度购买了 Rezolute 的新头寸，价值约为 30,000 美元。Legal &amp; General Group Plc 在第二季度购买了 Rezolute 的新股份，价值约为 32,000 美元。Raymond James Financial Inc.在第二季度购买了 Rezolute 的新头寸，价值为 46,000 美元。最后，Paloma Partners Management Co 在第一季度购买了 Rezolute 的新头寸，价值为 48,000 美元。目前，82.97% 的股票由机构投资者持有。</p>
</div><h2>About Rezolute</h2>
<div class="lb-trans"><h2>关于 Rezolute</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.</p>
<div class="lb-trans"><p>Rezolute, Inc.是一家临床阶段的生物制药公司，专注于开发治疗与慢性葡萄糖失衡相关的代谢疾病的疗法。该公司的主要产品候选药物是 RZ358，一种人源单克隆抗体，目前正在进行针对先天性高胰岛素血症的 2b 期临床试验，这是一种极为罕见的儿童遗传疾病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Rezolute</li>
<li>Business Services Stocks Investing</li>
<li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Dell and HP Are Raising Prices—And Investors Should Take Note</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Rezolute 更好</li>
<li>商业服务股票投资</li>
<li>ServiceNow 的 70 亿美元赌注：恐慌还是机会？</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>戴尔和惠普正在涨价——投资者应注意</li>
<li>欧元区 STOXX 50 指数是什么？</li>
<li>为什么 DLocal 是 2026 年值得关注的顶级新兴市场金融科技股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlpMVA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=RZLT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rezolute Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rezolute 吗？</h2>
</div><p>Before you consider Rezolute, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rezolute 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Rezolute 并不在名单上。</p>
</div><p>While Rezolute currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rezolute 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Rezolute（纳斯达克代码：RZLT）的首席执行官购买了价值 50,880.00 美元的股票